Use of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound

Simple item page
dc.contributor.authorBozoglan H.
dc.contributor.authorErgene U.
dc.contributor.authorYoleri L.
dc.date.accessioned2024-07-22T08:20:08Z
dc.date.available2024-07-22T08:20:08Z
dc.date.issued2011
dc.description.abstractAcute myeloid leukemia (AML) is malignant tumor of haemopoietic precursor cells of non-lymphoid lineage. AML can atypically present with non-spesific cutaneous lesions or wounds. There are rare acute leukemia cases which present with genital ulcerations or pyoderma gangrenosum in the literature. The effect of acute leukemia on wound healing is not known, but it is thought that cytopenias and chemotherapy can impair wound healing in patients with leukemia. The effects of chemotherapeutic agents on wound healing are arguable. Here we present wound care strategies and simultaneously applied chemotherapy in an AML patient. © 2011 Elsevier Ltd.
dc.identifier.DOI-ID10.1016/j.transci.2011.06.016
dc.identifier.issn18781683
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18008
dc.language.isoEnglish
dc.subjectAdult
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectCytarabine
dc.subjectHumans
dc.subjectIdarubicin
dc.subjectLeukemia, Myeloid, Acute
dc.subjectMale
dc.subjectPancytopenia
dc.subjectPyoderma Gangrenosum
dc.subjectWound Healing
dc.subjectcytarabine
dc.subjectidarubicin
dc.subjectacute granulocytic leukemia
dc.subjectadult
dc.subjectarticle
dc.subjectcase report
dc.subjectclinical feature
dc.subjectdisease severity
dc.subjectdrug effect
dc.subjectdrug use
dc.subjecthuman
dc.subjectmale
dc.subjectpancytopenia
dc.subjectskin bruising
dc.subjectskin ulcer
dc.subjectsymptom
dc.subjecttreatment outcome
dc.subjectwound care
dc.titleUse of cytarabine and idarubicin in a newly diagnosed AML patient with a severe wound
dc.typeArticle

Files

Collections

Scopus Koleksiyonu